November 29, 2022

Marin M. Jukić, Ph.D., discusses his article titled “Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients .” Read the article here:

However, many patients do not respond to escitalopram treatment. while certain patients are not able to respond to escitalopram under any circumstances, in the fda-approved drug label for escitalopram recommends a daily dose of however, a dose increase from 10 to 20 milligrams of escitalopram per day predict escitalopram exposure for an individual patient would help in

Making the dose. 2c19 isoform of the cytochrome p450 enzyme the cyp2c19 gene is polymorphic, and common variant alleles cause either a loss or gain of the affects the escitalopram metabolism. in this study, we analyzed the data derived from 2,087 patients treated with escitalopram with the aim to quantify the an inactive cyp2c19 allele do not possess an active enzyme,

And they are usually three-fold increased escitalopram serum levels and three-fold increased genotype. because of the high expected drug exposure, the dose increase is very other hand, the patients carrying cyp2c19*17 gain the functioning allele, metabolizers. these patients exhibit a decrease in escitalopram serum levels, incidence of treatment failure compared with the

Carriers of normal cyp2c19 levels, dose increase has a potential to improve the treatment metabolism slows down, leading to the approximately 60% increase in therefore, the dose increase should not be considered in the elderly recommendations from the fda-approved drug label for escitalopram. in summary, the a major impact on escitalopram exposure and clinical treatment

Outcome, and support utility of pre-emptive cyp2c19 genotyping for the personalization of

Transcribed from video
AJP Author Spotlight: Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure By PsychiatryOnline